Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02886065 | A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | active not recruiting | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05767359 | CAR- PRISM (PRecision Intervention Smoldering Myeloma) | active not recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04094961 |
| Ixazomib + Pomalidomide + Dexamethasone In MM |
| active not recruiting |
| Phase 1 / Phase 2 |
| 52 |
| Omar Nadeem, MDOTHER |
| 1 |
| Mar 5, 2026 |
| clinicaltrials |
| NCT04656951 | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse(GMMG-DADA) | active not recruiting | Phase 2 | 67 | University of CologneOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | active not recruiting | Phase 2 | 50 | PETHEMA FoundationOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02659293 | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | active not recruiting | Phase 3 | 180 | University of ChicagoOTHER | 2 | Mar 4, 2026 | clinicaltrials |
| NCT03070327 | BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03729804 | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)((COBRA)) | active not recruiting | Phase 3 | 250 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03741127 | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | active not recruiting | Phase 1 | 100 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05271630 | Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant | active not recruiting | — | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03589222 | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | active not recruiting | Phase 2 | 62 | PETHEMA FoundationOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04764942 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | active not recruiting | Phase 1 / Phase 2 | 39 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05587972 | Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring | active not recruiting | N/A | 100 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05577000 | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Thomas Martin, MDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06126341 | A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders | active not recruiting | — | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05391750 | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | active not recruiting | Phase 1 | 7 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04977024 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | active not recruiting | Phase 2 | 63 | GeoVax, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)(iMMagine-1) | active not recruiting | Phase 2 | 136 | Kite, A Gilead CompanyINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma(Perseus) | active not recruiting | Phase 3 | 709 | Stichting European Myeloma NetworkNETWORK | 13 | Feb 10, 2026 | clinicaltrials |
| NCT04221178 | Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission | active not recruiting | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04751877 | Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | active not recruiting | Phase 3 | 270 | Poitiers University HospitalOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04850846 | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | active not recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 220 | AbbVieINDUSTRY | 2 | Feb 6, 2026 | clinicaltrials |
| NCT00572169 | UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | active not recruiting | Phase 3 | 177 | University of ArkansasOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03617731 | Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | active not recruiting | Phase 3 | 662 | University of Heidelberg Medical CenterOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65(DFCI 10-106) | active not recruiting | Phase 3 | 729 | Paul Richardson, MDOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT02718833 | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT01269593 | PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | active not recruiting | Early Phase 1 | 63 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05954780 | Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma(SEATTLE) | active not recruiting | — | 75 | iOMEDICO AGINDUSTRY | 2 | Jan 14, 2026 | clinicaltrials |
| NCT03030261 | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | active not recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 2 | Jan 12, 2026 | clinicaltrials |
| NCT01746849 | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04370483 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 1 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05560399 | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma(CC-220) | active not recruiting | Early Phase 1 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma(IZALCO) | active not recruiting | Phase 2 | 118 | SanofiINDUSTRY | 7 | Dec 29, 2025 | clinicaltrials |
| NCT05130827 | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05775094 | A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | active not recruiting | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | active not recruiting | Phase 2 | 79 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05801939 | Cevostamab Following CAR T Cell Therapy for RRMM | active not recruiting | Phase 2 | 30 | University of PennsylvaniaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04270409 | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 337 | SanofiINDUSTRY | 24 | Dec 12, 2025 | clinicaltrials |
| NCT04184050 | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | active not recruiting | Phase 1 | 100 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT05028348 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | active not recruiting | Phase 3 | 117 | European Myeloma Network B.V.NETWORK | 4 | Dec 4, 2025 | clinicaltrials |
| NCT03829371 | STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | active not recruiting | Phase 4 | 450 | University of Turin, ItalyOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT01838512 | Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) | active not recruiting | — | 2,555 | Bristol-Myers SquibbINDUSTRY | 6 | Dec 2, 2025 | clinicaltrials |
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma(DREAMM 9) | active not recruiting | Phase 1 | 118 | GlaxoSmithKlineINDUSTRY | 10 | Nov 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2026source: clinicaltrials